Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Lymphoma, T-Cell, Cutaneous 8Mycosis Fungoides 7Sezary Syndrome 5Carcinoma, Non-Small-Cell Lung 5Lymphoma 3Leukemia, Myeloid, Acute 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 2Lung Neoplasms 2Leukemia 2Carcinoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Sarcoma, Kaposi 1Recurrence 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1HIV Infections 1Congenital Abnormalities 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Anemia, Refractory, with Excess of Blasts 1Aggression 1Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) 1

Interventions

Brentuximab Vedotin 3Bexarotene 2Vitamin B 12 1Salvia hispanica seed extract 1Methotrexate 1Lenalidomide 1Folic Acid 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Bexarotene × Clear all
NCT01578499 2021-01-05

ALCANZA

Takeda

Phase 3 Completed
131 enrolled 24 charts
DermatologicLymphoid

Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

NCT01134341 2019-12-18

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Acrotech Biopharma Inc.

Phase 1 Completed
34 enrolled
DermatologicLymphoid

Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡